Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + R-ICE in relapsed/refractory DLBCL
NCT05364424Phase 1Completed
- Sponsor
- Roche
- Start
- Nov 2022
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Primary endpoint: Objective Response Rate at 2.5 years. Started Nov 2022; status: completed.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05364424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364424.